Compare Stocks: BRNS, DTSQ, BNR, and BMEA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.37 +0.7%	$1.29	$0.87 ▼ $2.99	$99.30M	-0.28	521,271 shs	572,719 shs
BNR Burning Rock Biotech	$9.78 +5.7%	$9.25	$6.79 ▼ $41.72	$102.87M	1.34	5,281 shs	4,630 shs
BRNS Barinthus Biotherapeutics	$0.62 +1.5%	$0.63	$0.51 ▼ $1.83	$25.40M	-0.39	33,554 shs	11,679 shs
DTSQ DT Cloud Star Acquisition	$11.40 +0.9%	$11.32	$10.45 ▼ $12.90	$100.58M	-0.01	1,474 shs	100 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	0.00%	+3.79%	+8.73%	-3.52%	-23.03%
BNR Burning Rock Biotech	0.00%	+3.99%	+9.27%	-32.60%	+5.16%
BRNS Barinthus Biotherapeutics	0.00%	+5.19%	+3.62%	-10.29%	-45.46%
DTSQ DT Cloud Star Acquisition	0.00%	+0.63%	+0.72%	+1.24%	+9.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.37 +0.7%	$1.29	$0.87 ▼ $2.99	$99.30M	-0.28	521,271 shs	572,719 shs
BNR Burning Rock Biotech	$9.78 +5.7%	$9.25	$6.79 ▼ $41.72	$102.87M	1.34	5,281 shs	4,630 shs
BRNS Barinthus Biotherapeutics	$0.62 +1.5%	$0.63	$0.51 ▼ $1.83	$25.40M	-0.39	33,554 shs	11,679 shs
DTSQ DT Cloud Star Acquisition	$11.40 +0.9%	$11.32	$10.45 ▼ $12.90	$100.58M	-0.01	1,474 shs	100 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	0.00%	+3.79%	+8.73%	-3.52%	-23.03%
BNR Burning Rock Biotech	0.00%	+3.99%	+9.27%	-32.60%	+5.16%
BRNS Barinthus Biotherapeutics	0.00%	+5.19%	+3.62%	-10.29%	-45.46%
DTSQ DT Cloud Star Acquisition	0.00%	+0.63%	+0.72%	+1.24%	+9.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	2.67	Moderate Buy	$8.20	498.54% Upside
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	543.40% Upside
DTSQ DT Cloud Star Acquisition	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRNS, DTSQ, BNR, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C-)
7/1/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/29/2026	DTSQ DT Cloud Star Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/16/2026	BMEA Biomea Fusion	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/15/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
5/28/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.17 per share	N/A
BNR Burning Rock Biotech	$77.16M	1.33	N/A	N/A	$7.28 per share	1.34
BRNS Barinthus Biotherapeutics	$14.97M	1.70	N/A	N/A	$1.40 per share	0.44
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$61.80M	-$0.29	N/A	N/A	N/A	N/A	-253.73%	-97.91%	11/3/2026 (Estimated)
BNR Burning Rock Biotech	-$7.92M	-$0.82	N/A	N/A	N/A	-11.57%	-10.98%	-7.33%	9/2/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/5/2026 (Estimated)
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BRNS, DTSQ, BNR, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	N/A	N/A	N/A	$19.21 million	N/A
8/6/2026	Q2 2026	BMEA Biomea Fusion	-$0.2235	-$0.12	+$0.1035	-$0.12	N/A	N/A
8/6/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/3/2026	Q2 2026	DTSQ DT Cloud Star Acquisition	N/A	$0.0630	N/A	$0.0630	N/A	N/A
6/9/2026	Q1 2026	BNR Burning Rock Biotech	-$2.2884	-$0.20	+$2.0884	-$0.25	$19.21 million	$15.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.47	3.47
BNR Burning Rock Biotech	0.06	3.05	2.81
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
DTSQ DT Cloud Star Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
BNR Burning Rock Biotech	30.03%
BRNS Barinthus Biotherapeutics	25.20%
DTSQ DT Cloud Star Acquisition	N/A

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	10.60%
BNR Burning Rock Biotech	30.30%
BRNS Barinthus Biotherapeutics	8.50%
DTSQ DT Cloud Star Acquisition	52.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	72.48 million	64.80 million	Optionable
BNR Burning Rock Biotech	1,390	10.52 million	7.33 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
DTSQ DT Cloud Star Acquisition	N/A	8.90 million	4.19 million	N/A

BRNS, DTSQ, BNR, and BMEA Headlines

Recent News About These Companies

DT Cloud Star Relocates Principal Executive Office to Jersey City

August 19, 2026 | tipranks.com

DT Cloud Star Acquisition Corporation (NASDAQ:DTSQ) Short Interest Down 57.6% in July

August 15, 2026 | marketbeat.com

DT Cloud Star Acquisition (NASDAQ:DTSQ) Trading Up 0.2% - Should You Buy?

August 7, 2026 | marketbeat.com

DT Cloud Star Faces Nasdaq Delisting Amid Compliance Issues

July 20, 2026 | tipranks.com

DT Cloud Star Announces Board Director Resignation

April 10, 2026 | tipranks.com

DT Cloud Star Faces Nasdaq Public Holder Deficiency Notice

April 9, 2026 | tipranks.com

DT Cloud Star to Merge with PrimeGen US

February 4, 2026 | tipranks.com

DT Cloud Star SPAC Extends Deadline for Business Combination

January 7, 2026 | tipranks.com

DT Cloud Star Acquisition Cancels Planned Shareholder Meeting

December 22, 2025 | tipranks.com

DT Cloud Star Adjourns Shareholder Meeting to December 22

December 15, 2025 | tipranks.com

DT Cloud Star Appoints Dr. Zhou as Director

November 28, 2025 | tipranks.com

DT Cloud Star Approves Business Combination Extension

October 24, 2025 | tipranks.com

DT Cloud Star Adjourns Shareholder Meeting to October 22

October 20, 2025 | tipranks.com

DT Cloud Star Schedules Shareholder Meeting Adjournment

October 15, 2025 | tipranks.com

DT Cloud Star Meeting Adjourned to October 15

October 8, 2025 | tipranks.com

DT Cloud Star Terminates Promissory Note Agreement

July 31, 2025 | tipranks.com

DT Cloud Star Appoints Sam Zheng Sun as CEO

April 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, DTSQ, BNR, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.37 +0.01 (+0.74%)

As of 08/21/2026 04:00 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Burning Rock Biotech NASDAQ:BNR

$9.78 +0.53 (+5.73%)

As of 08/21/2026 04:00 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.62 +0.01 (+1.54%)

As of 08/21/2026 02:30 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

DT Cloud Star Acquisition NASDAQ:DTSQ

$11.40 +0.10 (+0.88%)

Closing price 08/21/2026 04:07 AM Eastern

Extended Trading

$11.36 -0.04 (-0.39%)

As of 08/21/2026 04:07 AM Eastern

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, DTSQ, BNR, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, DTSQ, BNR, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, DTSQ, BNR, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, DTSQ, BNR, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

Burning Rock Biotech NASDAQ:BNR

Barinthus Biotherapeutics NASDAQ:BRNS

DT Cloud Star Acquisition NASDAQ:DTSQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRNS, DTSQ, BNR, and BMEA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRNS, DTSQ, BNR, and BMEA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRNS, DTSQ, BNR, and BMEA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS, DTSQ, BNR, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

Burning Rock Biotech NASDAQ:BNR

Barinthus Biotherapeutics NASDAQ:BRNS

DT Cloud Star Acquisition NASDAQ:DTSQ

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools